1[2]Bristow MR, David Port J ,Kelly RA. Principles of pharmacologic management of chronic heart failure. In: Antman EM. Cardiovascular therapeutics. 2nd ed. Philadelphia: WB Saunders Co. ,2002. 300-324.
2[3]McClean DR, Ikram H, Garlick AH, et al. The clinical,cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor in patients with chronic heart failure. J Am Coll Cardiol, 2000, 36:479-486.
3[4]Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol, 1999,83:376-378.
4[5]Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (Enbrel) in patients with advanced heart failure. Circulation, 2001,103:1044-1047.
5Consensus recommendations for the management of chronic heart failure.On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure[].The American Journal of Cardiology.1999
